Italian researchers have compiled recent data from the literature on the efficacy of new treatments for myasthenia gravis, in particular complement inhibitors and fetal immunoglobulin receptor (FcRn) blockers.
- A Cochrane-type approach was used, resulting in a simple meta-analysis and a network meta-analysis,
- The observation windows for product efficacy were significantly different (26 weeks for eculizumab and ravulizimab, 28 days for efgartigimod, 43 days for rozanolixitumab, 12 weeks for zilucoplan and up to 52 weeks for rituximab),
- The authors confirm a better therapeutic benefit for complement inhibitors and FcRn compared with rituximab.
- The network meta-analysis argues in favour of efgartigimod in particular.
